1900 Wealth Management LLC Increases Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

1900 Wealth Management LLC boosted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 775 shares of the company’s stock after acquiring an additional 50 shares during the period. 1900 Wealth Management LLC’s holdings in IDEXX Laboratories were worth $320,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Sanctuary Advisors LLC acquired a new position in IDEXX Laboratories in the second quarter valued at $1,363,000. Czech National Bank grew its holdings in IDEXX Laboratories by 6.5% in the 3rd quarter. Czech National Bank now owns 16,766 shares of the company’s stock valued at $8,471,000 after buying an additional 1,028 shares during the period. Mather Group LLC. increased its stake in shares of IDEXX Laboratories by 3.9% during the 3rd quarter. Mather Group LLC. now owns 617 shares of the company’s stock valued at $312,000 after acquiring an additional 23 shares during the last quarter. Sovereign Financial Group Inc. lifted its holdings in shares of IDEXX Laboratories by 5.1% during the 3rd quarter. Sovereign Financial Group Inc. now owns 470 shares of the company’s stock worth $237,000 after acquiring an additional 23 shares during the period. Finally, Wedmont Private Capital boosted its position in shares of IDEXX Laboratories by 7.1% in the third quarter. Wedmont Private Capital now owns 2,842 shares of the company’s stock worth $1,343,000 after acquiring an additional 189 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

IDXX has been the subject of several research analyst reports. Stifel Nicolaus dropped their price target on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research report on Thursday, October 10th. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday. JPMorgan Chase & Co. cut their target price on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Morgan Stanley lowered their price target on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. Finally, Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $524.38.

IDEXX Laboratories Stock Down 1.7 %

Shares of NASDAQ:IDXX opened at $460.56 on Friday. The company has a market capitalization of $37.72 billion, a price-to-earnings ratio of 44.41, a price-to-earnings-growth ratio of 3.64 and a beta of 1.37. The company has a 50 day moving average of $426.81 and a two-hundred day moving average of $453.62. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $583.39. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the sale, the director now owns 905 shares in the company, valued at $380,498.20. This trade represents a 27.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 2.18% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.